Skip to content

About Us

Proteomics International Laboratories Ltd (ASX:PIQ) is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. Founded in 2001, the Company specialises in proteomics – the industrial scale study of the structure and function of proteins.

Proteomics International is a wholly-owned subsidiary and the trading name of Proteomics International Laboratories Ltd (PILL; ASX: PIQ). The company operates trading entities in the European Union, India, and the United States of America.

Proteomics International’s business model is to bring its pipeline of novel diagnostic tests, exemplified by Promarker®D, Promarker®Endo, Promarker®Eso and OxiDx, to major markets across the world, and drive additional R&D and product development activities through its analytical services revenue. This diversified model enables the group to drive optimum resource utilisation.

Proteomics International’s three strategic growth areas:

  1. Commercialisation: Market introduction and adoption of our first three products, PromarkerD, PromarkerEso, and PromarkerEndo.
  2. Precision Diagnostics Pipeline: Research activities to validate discovered unique biomarkers in advance of our formal product development process. Each new diagnostic area evaluated to solve unmet medical needs.
  3. Analytical Services: Cutting-edge, accredited analytical services on a commercial scale, accredited to ISO 17025 standards.

Proteomics International is a recognised global leader in the field of proteomics. The company operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.

Our Mission and Vision
Line 14

Our Mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

Our Vision is to help create a world where disease is detected early and cured simply. 

Our Values
Line 14

Proteomics International is committed to maintaining the highest standards of integrity and quality of results whilst acting lawfully, ethically and responsibly.

  • The Company will pursue operational and commercial excellence by using best practice approaches in our decision-making process focusing on continuous development, accountability and teamwork in all aspects of our business.
  • In order to achieve these goals, we will ensure our employees and business partners have the appropriate skills and resources to perform their work effectively and efficiently and that all stakeholders (including investors, customers, suppliers and regulators) are aware of the Company’s values and our intention to uphold them.
  • We will foster an open and supportive environment in all activities and relationships. A key attribute to this approach is maintaining responsible long-term management.

A critical component of Proteomics International’s strategy is maintaining its reputation for performing R&D and delivering its services in a reliable and credible manner. This is reflected in the strategic pillars of ground-breaking research and quality analytical services, and means that Proteomics International must put its reputation at the centre of everything it does.

Our Commitment
Line 14

The Company and its subsidiary companies are committed to conducting all of its business activities in accordance with the above stated values. The Board will ensure that all employees are given appropriate training on the Company’s values and the senior management group will continually demonstrate and reinforce such values in all interactions with staff.

We believe that our pursuit of these values will cement a positive reputation for the Company in the community as a reliable, responsible and ethical organisation.

Our Code of Conduct
Line 14
  • Be open, honest and trustworthy and always do what we say we will do (Integrity and Accountability).
  • Generate reliable data and results of the highest quality (Quality, Discipline and Excellence).
  • Create novel products and services in areas of significant unmet need across medicine, veterinary health and agriculture (Innovation).
Our Quality
Line 14
Proteomics International is experienced in delivering quality, accurate results that help progress your research and business. Accreditation recognises Proteomics Internationals’ ability to consistently achieve technically valid, traceable and reproducible results.
  • Proteomics International’s WA Proteomics Facility (WAP) is accredited for compliance with ISO/IEC 17025 since 2009 (NATA accreditation number 16838). For further details of this accreditation, please refer to the NATA website.
  • In Australia, accreditation is assessed by NATA (the National Association of Testing Authorities). ISO/IEC 17025 is recognised worldwide as the main ISO standard used by testing and calibration laboratories, and is the most widely used laboratory standard for US Federal testing laboratories. ISO/IEC 17025 is used by the FDA’s testing facilities. In 2009, the company’s laboratory was the first facility in the world to receive ISO 17025 accreditation for proteomics services.
  • Proteomics International is accredited by NATA for compliance with NPAAC Standards and with ISO 15189:2022 to operate and deliver clinical pathology services. Details of this accreditation may be found on the NATA website.